Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''") |
m |
||
Line 11: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
=All lines of therapy= | =All lines of therapy= | ||
==Belzutifan monotherapy {{#subobject:egac3f|Regimen=1}}== | ==Belzutifan monotherapy {{#subobject:egac3f|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:py42s1|Variant=1}}=== | ===Regimen {{#subobject:py42s1|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
Line 21: | Line 20: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ Jonasch et al. 2021 (MK-6482-004)] |
|2018-2019 | |2018-2019 | ||
| style="background-color:#91cf61" |Phase 2 (RT) | | style="background-color:#91cf61" |Phase 2 (RT) | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Belzutifan (Welireg)]] 120 mg PO once per day | *[[Belzutifan (Welireg)]] 120 mg PO once per day | ||
− | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34818478/ Pubmed] NCT03401788 | + | # '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34818478/ Pubmed] NCT03401788 |
− | |||
[[Category:Renal cell carcinoma regimens]] | [[Category:Renal cell carcinoma regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Renal cell carcinomas]] | [[Category:Renal cell carcinomas]] |
Revision as of 15:16, 26 February 2023
Section editor transclusions Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Belzutifan monotherapy
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Jonasch et al. 2021 (MK-6482-004) | 2018-2019 | Phase 2 (RT) |
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article Pubmed NCT03401788